Study of Anti-MUC1-monoclonal-antibody-AR20-5 in pancreatic cancer patients
Latest Information Update: 22 Aug 2023
At a glance
- Drugs Anti-MUC1 monoclonal antibody AR20-5 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 21 Aug 2023 According to a CanariaBio media release, the company is planning to initiate clinical trials to assess the safety and efficacy of MAb-AR20.5 in patients with pancreatic cancer.
- 21 Aug 2023 According to a CanariaBio media release, the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug product, MAb-AR20.5 for pancreatic cancer.
- 14 Nov 2016 New trial record